Compare RVPH & LSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVPH | LSBK |
|---|---|---|
| Founded | 2006 | 1891 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0M | 110.0M |
| IPO Year | N/A | 2006 |
| Metric | RVPH | LSBK |
|---|---|---|
| Price | $0.28 | $14.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.33 | N/A |
| AVG Volume (30 Days) | ★ 7.3M | 12.4K |
| Earning Date | 11-13-2025 | 01-23-2026 |
| Dividend Yield | N/A | ★ 2.43% |
| EPS Growth | N/A | ★ 105.28 |
| EPS | N/A | ★ 1.21 |
| Revenue | N/A | ★ $27,774,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.26 |
| Revenue Growth | N/A | ★ 9.61 |
| 52 Week Low | $0.25 | $11.50 |
| 52 Week High | $2.17 | $16.95 |
| Indicator | RVPH | LSBK |
|---|---|---|
| Relative Strength Index (RSI) | 26.65 | 55.90 |
| Support Level | $0.48 | $14.53 |
| Resistance Level | $0.63 | $14.98 |
| Average True Range (ATR) | 0.07 | 0.22 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 6.44 | 38.94 |
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.